HOPO Therapeutics
Overview
Theranostics combine precise diagnostic imaging with radioligand therapies, offering a new approach to targeted oncological treatment.
The Issue
Current radioligand therapies require time, resource-consuming heating, and purification processes due to suboptimal metal binding chemistry which greatly limits scalability despite promising clinical outcomes in late-stage metastasized cancers.
Approach
HOPO Therapeutics’ protein-based delivery platform for therapeutic and diagnostic isotopes offers a streamlined and transformative ‘cold-kit’ approach to theranostics by bypassing traditional lengthy heating and purification processes.
MTM Student Engagement
This project will explore the market forces that will guide target selection, early business development strategy, and regulatory strategy for a preclinical platform asset.
Project Brief
